Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
NHS Commissioning Board (operating under the name of NHS England)
NHS England, Rutland House, 2nd Floor
Runcorn
WA7 2ES
UK
E-mail: Katie.noonan@nhs.net
NUTS: UK
Internet address(es)
Main address: https://nhsengland.bravosolution.co.uk
Address of the buyer profile: https://nhsengland.bravosolution.co.uk
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS Framework for the NHS London Region, Branded Medicines – Tranche B, Cytokine Modulators and Other Monoclonal Antibodies and Antiretrovirals
II.1.2) Main CPV code
33600000
II.1.3) Type of contract
Supplies
II.1.4) Short description
CM/PHR/16/5515/01 — 1.9.2019 to 31.8.2021 – NHS Framework for the NHS London Region, Branded Medicines – Tranche B with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
CM/PHR/16/5515/02 — 1.9.2019 to 31.8.2020 — NHS Framework for the NHS London Region, Branded Medicines – Annual Tranche — Cytokine Modulators and other monoclonal antibodies with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.
CM/PHR/16/5515/03 — 1.9.2019 to 31.8.2020 – NHS Framework for the NHS London Region, Branded Medicines — Antiretrovirals with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.
II.1.6) Information about lots
This contract is divided into lots:
Yes
II.1.7) Total value of the procurement
Value excluding VAT:
503 860 674.00
GBP
II.2) Description
Lot No: 1
II.2.1) Title
NHS Framework for the NHS London Region, Branded Medicines – Tranche B with an Option to extend (at the Authority’s Discretion) for a Period or Periods Up to a Total of 24 Months
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKI
Main site or place of performance:
Please refer to schedule 8 of the framework agreement.
II.2.4) Description of the procurement
CM/PHR/16/5515/01 — 1.9.2019 to 31.8.2021 – NHS Framework for the NHS London Region, Branded Medicines – Tranche B with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
Products associated with the lots are listed on document No 05 of the Invitation to offer.
Each individual National product code (NPC) pack description in each of the regions (London) is deemed to be a separate product for the application of the award criteria.
There is no restriction on the number of products that bidders can offer for, or be awarded.
The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England.
The framework may also be used by private sector contractors and agents working on behalf of the above.
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: 1
Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: 1
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
NHS Framework for the NHS London Region, Branded Medicines – Annual Tranche — Cytokine Modulators and Other Monoclonal Antibodies with an Option to extend (at the Authority’s Discretion) for a Period
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKI
II.2.4) Description of the procurement
CM/PHR/16/5515/02 — 1.9.2019 to 31.8.2020 — NHS Framework for the NHS London Region, Branded Medicines – Annual Tranche — Cytokine Modulators and other monoclonal antibodies with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.
Products associated with the lots are listed on document No 05 of the Invitation to offer.
Each individual National product code (NPC) pack description in each of the regions (London) is deemed to be a separate product for the application of the award criteria.
There is no restriction on the number of products that bidders can offer for, or be awarded.
The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England.
The framework may also be used by private sector contractors and agents working on behalf of the above.
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: 1
Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: 1
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
NHS Framework for the NHS London Region, Branded Medicines — Antiretrovirals with an Option to extend (at the Authority’s Discretion) for a Period or Periods Up to a total of 12 Months
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKI
II.2.4) Description of the procurement
CM/PHR/16/5515/03 — 1.9.2019 to 31.8.2020 – NHS Framework for the NHS London Region, Branded Medicines — Antiretrovirals with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.
Products associated with the lots are listed on document No 05 of the Invitation to offer.
Each individual National product code (NPC) pack description in each of the regions (London) is deemed to be a separate product for the application of the award criteria.
There is no restriction on the number of products that bidders can offer for, or be awarded.
The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England.
The framework may also be used by private sector contractors and agents working on behalf of the above.
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: 1
Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: 1
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2019/S 050-114370
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
05/07/2019
V.2.2) Information about tenders
Number of tenders received: 33
Number of tenders received by electronic means: 33
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
NHS Comissioning Boards (Operating under the name of NHS England)
Runcorn
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 503 860 674.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
Awarded suppliers:
— AbbVie Ltd,
— Amgen Ltd,
— Astellas Pharma Ltd,
— Aventis Pharma Ltd Tranding as Sanofi,
— Biogen Idec UK Ltd,
— Bristol-Myers Squibb Pharmaceuticals Ltd,
— Daiichi Sankyo UK Ltd,
— ELI Lilly and Company Ltd,
— Ferring Pharmaceutical,
— Gedeon Richter UK Ltd,
— MYLAN UK Healthcare Ltd,
— Gilead Sciences Ltd,
— Ipsen Ltd,
— Janssen Cilag Ltd,
— Fannin UK Ltd T/A Kent Pharmaceuticals Ltd,
— LEO Pharma,
— Merck Serono Ltd,
— Merck Sharp and Dohme (MSD),
— Napp Pharmaceuticals Ltd,
— Novartis Pharmaceutical UK Ltd,
— Novo Nordisk Ltd,
— Pfizer Ltd,
— Pharmasure Ltd,
— Roche Products Ltd,
— ROVI Biotech Ltd,
— Sandoz Ltd,
— Takeda UK Ltd,
— Techdow Pharma England Ltd,
— UCB Pharma Ltd,
— ViiV Healthcare Ltd.
VI.4) Procedures for review
VI.4.1) Review body
The NHS Commissioning Board (Operating Under the Name of NHS England)
NHS England, Rutland House, Second Floor
Runcorn
WA7 2ES
UK
VI.5) Date of dispatch of this notice
09/09/2019